Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,663 recruiting studies in this area right now.
By phase
- Not applicable9,825
- Phase 24,462
- Phase 12,741
- Phase 1/Phase 21,689
- Phase 31,402
- Phase 2/Phase 3281
- Phase 4263
Top conditions
- Breast Cancer1,228
- Cancer660
- Prostate Cancer657
- Colorectal Cancer496
- Lung Cancer428
- Ovarian Cancer337
- Multiple Myeloma329
- Gastric Cancer300
- Pancreatic Cancer295
- Acute Myeloid Leukemia293
- Hepatocellular Carcinoma284
- Solid Tumor258
- Advanced Solid Tumor256
- Cervical Cancer231
- Head and Neck Cancer229
- Endometrial Cancer204
- Advanced Solid Tumors195
- Esophageal Cancer193
Leading sponsors
- M.D. Anderson Cancer Center451
- Fudan University313
- Sun Yat-sen University290
- Memorial Sloan Kettering Cancer Center289
- National Cancer Institute (NCI)288
- Mayo Clinic238
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center144
- AstraZeneca133
- University Health Network, Toronto125
Where studies are running
- California1,428
- Texas640
- Arizona513
- Florida446
- Alabama420
- New York411
- Massachusetts339
- Maryland329
- New Jersey268
- Pennsylvania242
Recruiting studies20,663 total
- NCT04991922Recruiting
Registry study collecting genetic test results for cancer care
This study enrolls people who have (or might have) cancer so the researchers can collect genetic and treatment information. The goal is to better understand how different cancers behave and how people respond to treatment, which may help improve future care.
Waltham, MassachusettsAges 18 years+ - NCT04990921RecruitingPhase 2
Palliative radiation plus pembrolizumab for metastatic breast cancer
This trial studies whether adding a focused, comfort-focused form of radiation (SBRT) to pembrolizumab can help people with stage IV breast cancer that cannot be removed with surgery. You may be eligible if you can receive palliative SBRT and have measurable tumors, and if you meet prior-therapy and blood/health criteria.
Louisville, KentuckyAges 18 years+ - NCT04991103RecruitingPhase 2
Testing delaying stem cell transplant after early myeloma response
This Phase 2 study tests whether people with newly diagnosed multiple myeloma can safely delay or avoid an immediate stem cell transplant if they respond well to early treatment. It aims to see if this “response-adapted” approach can still control the disease while reducing the need for upfront transplant for some patients.
Birmingham, AlabamaAges 18 years+ - NCT04991025RecruitingPhase 2
Certolizumab added to chemo and nivolumab for operable lung cancer
This Phase 2 study tests whether adding certolizumab (an immune-targeting medicine) to standard chemo plus nivolumab can improve outcomes in people with certain operable non-small cell lung cancers. The goal is to see if this combination works better than standard treatment before surgery.
Basking Ridge, New JerseyAges 18 years+ - NCT04991870RecruitingPhase 1
Early-stage immune cell therapy for recurrent grade 4 brain tumors
This Phase 1 trial tests a gene-edited immune cell treatment given into the brain to treat recurrent (returning) grade 4 glioblastoma or related tumors. It aims to find a safe dose and see whether the treatment can slow tumor growth.
Houston, TexasAges 12 years+ - NCT04992559RecruitingPhase 2
Toripalimab after surgery and chemoradiation for head and neck cancer
This trial studies toripalimab to lower the risk of the cancer coming back after surgery and additional chemo-radiation. It may help the immune system “finish the job” after your main treatment, especially if you have higher-risk features.
Guangzhou, GuangdongAges 18–70 - NCT04992728Recruiting
Testing a special prostate MRI to match cancer maps
This study uses a special kind of MRI to better “map” prostate cancer inside the prostate. Researchers compare the MRI results with the detailed tissue exam after prostate surgery to see how accurate the imaging is.
La Jolla, CaliforniaAges 18 years+ - NCT04993014RecruitingPhase 2
De-escalating treatment after HER2-positive breast cancer responds
This study looks at whether some people with HER2-positive breast cancer can safely receive less (de-escalated) treatment after they finish chemotherapy plus HER2-targeted drugs before surgery. It specifically focuses on people whose cancer shows a complete response on the surgery pathology report.
São PauloAges 18 years+ - NCT04993131Recruiting
Liver transplant for non-surgical bile duct cancer
This trial studies liver transplantation for people with a specific type of bile duct cancer near the liver that cannot be safely removed by surgery. It aims to improve outcomes by offering a transplant after the cancer responds to chemotherapy and spread has been ruled out on scans.
OsloAges 18 years+ - NCT04994067Recruiting
Registering radiation given during breast-conserving surgery
This study records details about radiation delivered while your surgery is happening for certain early breast cancers or pre-cancers. It may help doctors better understand who benefits most from this “intra-operative” radiation approach.
The Bronx, New YorkAges 18 years+ - NCT04995003RecruitingPhase 1
HER2 CAR T plus pembrolizumab for advanced HER2 sarcoma
This Phase 1 study tests a personalized immune-cell treatment (HER2 CAR T cells) given with an immune “checkpoint” medicine (pembrolizumab or another checkpoint blocker) to shrink advanced HER2-positive sarcoma. It may help patients whose cancer is progressing or coming back after prior treatment.
Houston, TexasAges 1–25 - NCT04996732Recruiting
Long-term follow-up study for people treated for cancer
This study looks at how people who have finished treatment for cancer are doing over the long term. It uses information from a cancer center registry to understand survivorship and outcomes after surgery and/or other treatments.
ShanghaiAges Any age - NCT04997096Recruiting
Exercise during chemo to prevent weakness from low movement
This study tests whether a structured exercise program during chemotherapy can help prevent physical decline (“immobility,” like getting weaker or moving less) in people with certain ovarian or endometrial cancers. If you’re eligible, you may be guided to exercise while receiving standard chemo, and you’ll have blood tests to track changes.
Boston, MassachusettsAges 18 years+ - NCT04996121RecruitingPhase 1/Phase 2
Drug for tumors with NTRK or ROS1 gene fusions
This trial studies an investigational pill (XZP-5955) for solid tumors that have specific gene changes: NTRK or ROS1 fusions. It is meant for people whose cancer is advanced or has spread, and who may not have good standard treatment options.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04996017RecruitingPhase 3
Atezolizumab after surgery for malignant pleural mesothelioma
This study tests whether atezolizumab given after surgery and chemotherapy can lower the risk of mesothelioma coming back compared with a placebo. It may help by boosting the immune system to control remaining microscopic cancer cells.
Meldola, ITAòYAges 18 years+ - NCT04996875RecruitingPhase 2
Bezuclastinib for advanced mast cell disease
This Phase 2 study tests bezuclastinib, a targeted medicine, in people with advanced systemic mastocytosis (including certain advanced forms with blood cancers). It aims to shrink measurable disease and improve symptoms, while helping people who may also need treatment for an associated blood cancer.
Birmingham, AlabamaAges 18 years+ - NCT04997317RecruitingPhase 1/Phase 2
Lu-177 targeting drug for returning or growing meningioma
This Phase 1/2 study tests a targeted radioactive medicine (Lu-177-satoreotide) for meningiomas that keep coming back or keep growing. It works only if tumor imaging shows the tumor has the right “target” signal, and it aims to see how well it can control the disease and how safe it is.
Basel, Canton of Basel-CityAges 18 years+ - NCT04998669RecruitingPhase 2
Loncastuximab plus rituximab for relapsed follicular lymphoma
This Phase 2 study tests whether loncastuximab, combined with rituximab, can shrink and control follicular lymphoma that has come back or not responded to prior treatment. It may help people who still have active disease that needs treatment and meet specific scan and blood test requirements.
Fort Myers, FloridaAges 18 years+ - NCT04997837RecruitingPhase 3
Adjuvant chemo with or without PD-1 for stomach cancer after surgery
This Phase 3 trial studies whether adding an immune medicine called PD-1 (given as an “inhibitor”) to standard chemotherapy and chemoradiation after stomach/GEJ cancer surgery can lower the risk of cancer coming back. You may qualify if you’ve had surgery removing the tumor and lymph nodes showed higher-risk disease.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04999007Recruiting
AI tool to help surgeons decide during rectal cancer surgery
This trial tests an artificial-intelligence support tool that helps surgeons make decisions during surgery for rectal cancer. If you qualify, the tool may be used alongside the surgical team to support safer, more effective care.
Wuhan, HubeiAges 18–85 - NCT05000801Recruiting
DC-AML cells for AML after remission but with relapse risk
This study tests DC-AML immune cells to help people with acute myeloid leukemia (AML) who are in remission but still show signs of leftover cancer cells or relapse risk. It may help the immune system attack AML cells, especially when a stem cell transplant is not an option.
Beijing, Beijing MunicipalityAges 18–70 - NCT05000294RecruitingPhase 1/Phase 2
Atezolizumab plus tivozanib for hard-to-treat “cold” cancers
This early-stage study tests whether combining atezolizumab and tivozanib can shrink advanced, hard-to-treat cancers that do not strongly activate the immune system (“immunologically cold”). It is for people whose cancer has already been treated or has no good standard options.
Gainesville, FloridaAges 18–99 - NCT05000697Recruiting
Watch-and-wait or chemo after rectal cancer radiation
This trial studies people with early-to-mid stage distal rectal cancer who may get radiation and chemotherapy, with an option that may include an extra drug (oxaliplatin). It also tests whether some people can safely follow a “watch and wait” plan instead of immediate additional treatment, aiming to reduce overtreatment while keeping cancer control.
Buenos AiresAges 18 years+ - NCT05000827Recruiting
PSMA PET scan to guide lymph node surgery in prostatectomy
This study tests whether a special prostate scan called PSMA PET/CT can help doctors decide which pelvic lymph nodes to remove during prostate surgery. It may improve who needs lymph node surgery by using scan results to guide the operation.
Nijmegen, GelderlandAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,663 recruiting oncology studies from the U.S. registry right now, out of 31,727 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.